Consumer Health / Over-the-Counter (OTC) Healthcare Products
Strategic Profile
Kenvue is the world's largest pure-play consumer health company by revenue, generating over $15 billion in annual sales. On November 3, 2025, Kimberly-Clark announced that it was acquiring Kenvue for a total enterprise value of $48.7 billion, with the acquisition expected to close around the second half of 2026. The company operates a diverse portfolio of trusted health and wellness brands targeting everyday consumer needs across multiple demographic segments.
Cyborg Score Rationale
The company has faced significant leadership transitions, with activist investor pressure from Starboard in March 2025 followed by CEO termination in July 2025. While Kenvue benefits from a dominant market position and iconic brands, the pending acquisition to Kimberly-Clark creates uncertainty and disrupts long-term strategic planning.
Top Insights
Kimberly-Clark acquisition valued at $48.7 billion announced in November 2025
CEO Thibaut Mongon terminated in July 2025 with company strategy review initiated
Company strategy focuses on 15 priority brands including Tylenol, Nicorette, Listerine, and Zyrtec
R&D spending targets approximately 3% of sales to maintain innovation competitiveness
Named Competitors
Clorox Consumer Health — Over-the-counter health and household products
Church & Dwight Consumer Products — Personal care and consumer health brands
Newell Consumer Portfolio — Diversified consumer products including health segments